BRIEF-Azurrx Biopharma Completes Enrollment In Trial Of Ms1819 To Treat Cystic Fibrosis Patients With Severe Exocrine Pancreatic Insufficiency

Reuters
22 Mar 2021

March 22 (Reuters) - AzurRx BioPharma Inc :

* AZURRX BIOPHARMA ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF MS1819 IN COMBINATION WITH PERT IN THE TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH SEVERE EXOCRINE PANCREATIC INSUFFICIENCY

* AZURRX BIOPHARMA - CONTINUE TO REMAIN ON TARGET TO REPORT TOPLINE RESULTS FROM COMBINATION THERAPY STUDY DURING Q2 OF 2021

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10